Table 2 Attitude of pharmacist regarding their role in the healthcare system (N = 396)
Roles | Education | Agree | Disagree | P-Value | Type | Agree | Disagree | P-Value | Experience | Agree | Disagree | P-Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
To educate patients and carers about the safe and appropriate use of medicines | B/M Pharm | 71 (17.9%) | 16 (4%) | 0.000* | State funded | 172 (43.4%) | 27 (6.8%) | 0.035 | < 5 years | 65 (16.4%) | 3 (0.8%) | 0.001 |
Pharm.D | 275 (69.4%) | 20 (5.1%) | Private | 183 (46.2%) | 14 (3.5%) | 5–10 years | 217 (54.8%) | 19 (4.8%) | ||||
Overseas | 9 (2.3%) | 5 (1.3%) | – | – | – | > 10 years | 73 (18.4%) | 19 (4.8%) | ||||
To monitor and report patients’ response to drug therapy | B/M Pharm | 74 (18.7%) | 13 (3.3%) | 0.002 | State funded | 176 (44.4%) | 23 (5.8%) | 0.086 | < 5 years | 64 (16.2%) | 4 (1.0%) | 0.022 |
Pharm.D | 276 (69.7%) | 19 (4.8%) | Private | 184 (46.5%) | 13 (3.3%) | 5–10 years | 219 (55.3%) | 17 (4.3%) | ||||
Overseas | 10 (2.5%) | 4 (1.0%) | – | – | – | > 10 years | 77 (19.4%) | 15 (3.8%) | ||||
To be available for clinician consultation during ward rounds | B/M Pharm | 71 (17.9%) | 16 (4.0%) | 0.031 | State funded | 169 (42.7%) | 30 (7.6%) | 0.031 | < 5 years | 65 (16.4%) | 3 (0.8%) | 0.009 |
Pharm.D | 268 (67.1%) | 27 (6.8%) | Private | 181 (45.7%) | 16 (4%) | 5–10 years | 211 (53.3%) | 25 (6.3%) | ||||
Overseas | 11 (2.8%) | 3 (0.8%) | – | – | – | > 10 years | 74 (18.7%) | 18 (4.5%) | ||||
To communicate or liaise with other healthcare professionals delivering patient care to facilitate positive health outcomes | B/M Pharm | 78 (19.7%) | 9 (2.3%) | 0.005 | State funded | 193 (48.7%) | 6 (1.5%) | 0.000* | < 5 years | 67 (16.9%) | 1 (0.3%) | 0.031 |
Pharm.D | 269 (67.9%) | 26 (6.6%) | Private | 163 (41.2%) | 34 (8.6%) | 5–10 years | 209 (52.8%) | 27 (6.8%) | ||||
Overseas | 9 (2.3%) | 5 (1.3%) | – | – | – | > 10 years | 80 (20.2%) | 12 (3.0%) | ||||
To collaborate with other healthcare professionals as part of a multidisciplinary team | B/M Pharm | 71 (17.9%) | 16 (4.0%) | 0.001 | State funded | 172 (43.4%) | 27 (6.8%) | 0.293 | < 5 years | 65 (16.4%) | 3 (0.8%) | 0.001 |
Pharm.D | 269 (67.9%) | 26 (5.5%) | Private | 177 (44.7%) | 20 (5.1%) | 5–10 years | 213 (53.8%) | 23 (5.8%) | ||||
Overseas | 9 (2.3%) | 5 (1.3%) | – | – | – | > 10 years | 71 (17.9%) | 21 (5.3%) | ||||
To provide advice to patients about their medication/s and/or health conditions | B/M Pharm | 71 (17.9%) | 16 (4.0%) | 0.000* | State funded | 175 (44.2%) | 24 (6.1%) | 0.083 | < 5 years | 64 (16.2%) | 4 (1.0%) | 0.000* |
Pharm.D | 278 (70.2%) | 17 (4.3%) | Private | 184 (46.5%) | 13 (3.3%) | 5–10 years | 222 (56.1%) | 14 (3.5%) | ||||
Overseas | 10 (2.5%) | 4 (1.0%) | – | – | – | > 10 years | 73 (18.4%) | 19 (4.8%) | ||||
To dispense and check supply of medicines to patient (counting pills, labelling, and accuracy checking) | B/M Pharm | 67 (16.9%) | 20 (5.1%) | 0.036 | State funded | 161 (40.7%) | 38 (9.6%) | 0.018 | < 5 years | 63 (15.9%) | 5 (1.3%) | 0.021 |
Pharm.D | 259 (65.4%) | 36 (9.1%) | Private | 176 (44.4%) | 21 (5.3%) | 5–10 years | 203 (51.3%) | 33 (8.3%) | ||||
Overseas | 11 (2.8%) | 3 (0.8%) | – | – | – | > 10 years | 71 (17.9%) | 21 (5.3%) | ||||
To provide a “closed shop” service: receiving prescriptions from a practitioner and dispense medicine to a patient only | B/M Pharm | 11 (2.8%) | 76 (19.2%) | 0.001 | State funded | 54 (13.6%) | 145 (36.6%) | 0.000 | < 5 years | 16 (4.0%) | 52 (13.1%) | 0.623 |
Pharm.D | 59 (14.9%) | 236 (59.6%) | Private | 24 (6.1%) | 173 (43.7%) | 5–10 years | 46 (11.6%) | 190 (48.0%) | ||||
Overseas | 8 (2.0%) | 6 (1.5%) | – | – | – | > 10 years | 16 (4.0%) | 76 (19.2%) | ||||
To check that prescriptions are written for the correct dose for the patient | B/M Pharm | 60 (15.2%) | 27 (6.8%) | 0.000* | State funded | 152 (38.4%) | 47 (11.9%) | 0.955 | < 5 years | 52 (13.1%) | 16 (4.0%) | 0.014 |
Pharm.D | 239 (60.4%) | 56 (14.1%) | Private | 150 (37.9%) | 47 (11.9%) | 5–10 years | 190 (48.0%) | 46 (11.6%) | ||||
Overseas | 3 (0.8%) | 11 (2.8%) | – | – | – | > 10 years | 60 (15.2%) | 32 (8.1%) | ||||
To check that prescriptions do not have any drug-drug interactions | B/M Pharm | 55 (13.9%) | 32 (8.1%) | 0.017 | State funded | 156 (39.4%) | 43 (10.9%) | 0.093 | < 5 years | 61 (15.4%) | 7 (1.8%) | 0.004 |
Pharm.D | 231 (58.3%) | 64 (16.2%) | Private | 140 (35.4%) | 57 (14.4%) | 5–10 years | 173 (43.7%) | 63 (15.9%) | ||||
Overseas | 10 (2.5%) | 4 (1.0%) | – | – | – | > 10 years | 62 (15.7%) | 30 (7.6%) | ||||
To check that a prescription is not contraindicated for the patient | B/M Pharm | 67 (16.9%) | 20 (5.1%) | 0.036 | State funded | 161 (40.7%) | 38 (9.6%) | 0.018 | < 5 years | 63 (15.9%) | 5 (1.3%) | 0.021 |
Pharm.D | 259 (65.4%) | 36 (9.1%) | Private | 176 (44.4%) | 21 (5.3%) | 5–10 years | 203 (51.3%) | 33 (8.3%) | ||||
Overseas | 11 (2.8%) | 3 (0.8%) | – | – | – | > 10 years | 71 (17.9%) | 21 (5.3%) | ||||
To advise clinicians and others about the cost-effectiveness of medicines | B/M Pharm | 74 (18.7%) | 13 (3.3%) | 0.002 | State funded | 176 (44.4%) | 23 (5.8%) | 0.086 | < 5 years | 64 (16.2%) | 4 (1.0%) | 0.022 |
Pharm.D | 276 (69.7%) | 19 (4.8%) | Private | 184 (46.5%) | 13 (3.3%) | 5–10 years | 219 (55.3%) | 17 (4.3%) | ||||
Overseas | 10 (2.5%) | 4 (1.0%) | – | – | – | > 10 years | 77 (19.4%) | 15 (3.8%) | ||||
To formally review a patient’s therapy and to make necessary changes to help promote positive health outcomes | B/M Pharm | 71 (17.9%) | 16 (4.0%) | 0.031 | State funded | 169 (42.7%) | 30 (7.6%) | 0.031 | < 5 years | 65 (16.4%) | 3 (0.8%) | 0.009 |
Pharm.D | 268 (67.7%) | 27 (6.8%) | Private | 181 (45.7%) | 16 (4.0%) | 5–10 years | 211 (53.3%) | 25 (6.3%) | ||||
Overseas | 11 (2.8%) | 3 (0.8%) | – | – | – | > 10 years | 74 (18.7%) | 18 (4.5%) | ||||
To supervise repeat prescriptions for patients according to agreed protocols | B/M Pharm | 71 (17.9%) | 16 (4.0%) | 0.000* | State funded | 172 (43.4%) | 27 (6.8%) | 0.035 | < 5 years | 65 (16.4%) | 3 (0.8%) | 0.001 |
Pharm.D | 275 (69.5) | 20 (5.1%) | Private | 183 (46.2%) | 14 (3.5%) | 5–10 years | 217 (54.8%) | 19 (4.8%) | ||||
Overseas | 9 (2.3%) | 5 (1.3%) | – | – | – | > 10 years | 73 (18.4%) | 19 (4.8%) | ||||
To make dose adjustments to a patient’s medicine using protocols established with prescribers | B/M Pharm | 71 (17.9%) | 16 (4.0%) | 0.000* | State funded | 175 (44.2%) | 24 (6.1%) | 0.062 | < 5 years | 64 (16.2%) | 4 (1.0%) | 0.000* |
Pharm.D | 278 (70.2%) | 17 (4.3%) | Private | 184 (46.5%) | 13 (3.3%) | 5–10 years | 222 (56.1%) | 14 (3.5%) | ||||
Overseas | 10 (2.5%) | 4 (1.0%) | – | – | – | > 10 years | 73 (18.4%) | 19 (4.8%) | ||||
To prescribe therapy for a patient following a clinician’s diagnosis (partnership or supplementary prescribing) | B/M Pharm | 79 (19.9%) | 8 (2.0%) | 0.001 | State funded | 187 (47.2%) | 12 (3.0%) | 0.816 | < 5 years | 66 (16.7%) | 2 (0.5%0 | 0.032 |
Pharm.D | 282 (71.2) | 13 (3.3%) | Private | 184 (46.5%) | 13 (3.3%) | 5–10 years | 224 (56.6%) | 12 (3.0%) | ||||
Overseas | 10 (2/5%) | 4 (1.0%) | – | – | – | > 10 years | 81 (20.5%) | 11 (2.8%) | ||||
To prescribe therapy for a patient independent of clinician’s diagnosis following an initial patient assessment (independent prescribing) | B/M Pharm | 55 (13.9%) | 32 (8.1%) | 0.017 | State funded | 156 (39.4%) | 43 (10.9%) | 0.093 | < 5 years | 61 (15.4%) | 7 (1.8%) | 0.004 |
Pharm.D | 231 (58.7%) | 64 (16.2%) | Private | 140 (35.4%) | 57 (14.4%) | 5–10 years | 173 (43.7%) | 63 (15.9%) | ||||
Overseas | 10 (2.5%) | 4 (1.0%) | – | – | – | > 10 years | 62 (15.7%) | 30 (7.6%) |